蝮蛇抗栓酶对糖尿病人血脂及纤维蛋白原的影响

Effect of Ahalysantinfarctase on lipemia and Fibrinogen in Diabetes Patients

本文用蝮蛇抗栓酶治疗NIDDM30例，与低分子右旋糖酐葡萄糖注射液（以下简称低右）加复方丹参注射液（以下简称丹参液）治疗NIDDM20例作为对照。对比观察了用药前后血脂的变化及纤维蛋白原的变化。结果显示：（1）对照组在治疗后仅纤维蛋白原明显下降（P＜0．01）；（2）治疗组在治疗后纤维蛋白原和甘油三酯均明显下降（P＜0．01和P＜0．05）。治疗组和对照组都使纤维蛋白原下降，二者间无显著差异（P＞0．05），由于蝮蛇抗栓酶既使纤维蛋白原下降，又使甘油三酯下降，故是治疗糖尿病的一种近期疗效较显著的辅助治疗药物。

30 and 20 NIDDM Patients were treated respectively with ahalysantinfarctase (trialgroup) and dextran 40 plas injection of compound danse (control group). The levels of lipemia and fibrinogen were measured before and after the treatrnent. Result: (1) Only fibrinogen lowed after treatment in control group (P< 0.01). (2)Both fibrinogn and lipemia lowed after the treatment intrial group (P< 0. 01 and P< 0. 05, respectively). No difference was noticed on fibrinogen in trial andcontrol group (P > 0. 05 ). Conclusion: Because ahalysantinfarctase can low both fibrinogen andlipemia, it is a more effective assistant medicine in diabetes patients.